LOUISVILLE, Ky. / Jan 03, 2024 / Business Wire / Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2023 (4Q23) on Monday, February 5, 2024, at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024.
To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BI4ed0098679fd435e8af0ab344fa47655.
Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.
A webcast of the 4Q23 earnings call may also be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/.
The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.
The company’s 4Q23 earnings news release is expected to include financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). A reconciliation of non-GAAP financial measures to financial results under GAAP, as well as management’s reasons for including non-GAAP financial measures, will be included in the company’s 4Q23 earnings news release, a copy of which will be available on the Investor Relations page of www.humana.com on February 5, 2024.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Last Trade: | US$293.97 |
Daily Change: | 16.19 5.83 |
Daily Volume: | 2,221,854 |
Market Cap: | US$35.400B |
November 12, 2024 October 30, 2024 October 24, 2024 October 23, 2024 August 19, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB